Cationic Liposome-Based Systems for Nucleic Acid Delivery: From the Formulation Development to Therapeutic Applications

Advances in Predictive, Preventive and Personalised Medicine

Volumn 4, Issue , 2013, Pages 153-184

  Faneca, Henrique ^a   Cardoso, Ana Luísa ^a   Trabulo, Sara ^a   Duarte, Sónia ^a   de Lima, Maria C Pedroso ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cationic liposomes; Gene therapy; Lipoplexes; Nucleic acid delivery; Personalized medicine; Targeting ligands

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA INTERFERON; CATIONIC LIPOSOME; CHOLESTEROL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; E1A PROTEIN; FOLATE RECEPTOR; FOLIC ACID; GANCICLOVIR; HEMAGGLUTININ; IMATINIB; INTERLEUKIN 13; LIGAND; LIPOPLEX; LIPOSOME; MESSENGER RNA; NUCLEIC ACID; OBLIMERSEN; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; TRANSFERRIN; UNCLASSIFIED DRUG; VELIMOGENE ALIPLASMID; VIRUS VECTOR;

ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; METASTATIC MELANOMA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEIC ACID DELIVERY SYSTEM; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RNA INTERFERENCE;

EID: 84903908433     PISSN: 22113495     EISSN: 22113509     Source Type: Book Series    
DOI: 10.1007/978-94-007-6010-3__6     Document Type: Article

References (139)

1. Meade BR, Dowdy SF (2007) Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 59: 134-140.
2. Opalinska JB, Gewirtz AM (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 1: 503-514.
3. Pedroso de Lima MC, Simoes S, Pires P, Faneca H, Duzgunes N (2001) Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev 47: 277-294.
4. Somia N, Verma IM (2000) Gene therapy: trials and tribulations. Nat Rev Genet 1: 91-99.
5. Torchilin VP (2008) Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90: 604-610.
6. Veldhoen S, Laufer SD, Restle T (2008) Recent developments in peptide-based nucleic acid delivery. Int J Mol Sci 9: 1276-1320.
7. Wiethoff CM, Middaugh CR (2003) Barriers to nonviral gene delivery. J Pharm Sci 92: 203-217.
8. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
9. Heitz F, Morris MC, Divita G (2009) Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157: 195-206.
10. Pfeifer A, Verma IM (2001) Gene therapy: promises and problems. Annu Rev Genomics Hum Genet 2: 177-211.
11. Robbins PD, Tahara H, Ghivizzani SC (1998) Viral vectors for gene therapy. Trends Biotechnol 16: 35-40.
12. Mountain A (2000) Gene therapy: the first decade. Trends Biotechnol 18: 119-128.
13. Pedroso de Lima MC, Simoes S, Pires P, Gaspar R, Slepushkin V, Duzgunes N (1999) Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. Mol Membr Biol 16: 103-109.
14. El-Aneed A (2004) An overview of current delivery systems in cancer gene therapy. J Control Release 94: 1-14.
15. Lechardeur D, Verkman AS, Lukacs GL (2005) Intracellular routing of plasmid DNA during non-viral gene transfer. Adv Drug Deliv Rev 57: 755-767.
16. Simoes S, Filipe A, Faneca H, Mano M, Penacho N, Duzgunes N, Pedroso de Lima MC (2005) Cationic liposomes for gene delivery. Expert Opin Drug Deliv 2: 237-254.
17. Li S, Huang L (2000) Nonviral gene therapy: promises and challenges. Gene Ther 7: 31-34.
18. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7417.
19. Montier T, Benvegnu T, Jaffres PA, Yaouanc JJ, Lehn P (2008) Progress in cationic lipidmediated gene transfection: a series of bio-inspired lipids as an example. Curr Gene Ther 8: 296-312.
20. Gene Therapy Clinical Trials Worldwide (2011) [cited; The journal of gene medicine website for Gene Therapy Clinical Trials Worldwide]. Available from: http://www. wiley. co. uk/genmed/clinical/. Accessed 7 Jan 2013.
21. Pedroso de Lima MC, Neves S, Filipe A, Duzgunes N, Simoes S (2003) Cationic liposomes for gene delivery: from biophysics to biological applications. Curr Med Chem 10: 1221-1231.
22. Tros de Ilarduya C, Sun Y, Duzgunes N (2010) Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 40: 159-170.
23. Marshall J, Yew NS, Eastman SJ, Jian C, Schelue RK, Cheng SH (1999) Cationic lipidmediated gene delivery to the airways. In: Huang L, Hung M-C, Wagner E (eds) Nonviral vectors for gene therapy. Academic Press, San Diego.
24. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269: 2550-2561.
25. Koynova R, Tenchov B (2010) Cationic lipids: molecular structure/transfection activity relationships and interactions with biomembranes. Top Curr Chem 296: 51-93.
26. MacDonald RC, Rakhmanova VA, Choi KL, Rosenzweig HS, Lahiri MK (1999) O-ethylphosphatidylcholine: a metabolizable cationic phospholipid which is a serumcompatible DNA transfection agent. J Pharm Sci 88: 896-904.
27. Faneca H, Simoes S, Pedroso de Lima MC (2002) Evaluation of lipid-based reagents to mediate intracellular gene delivery. Biochim Biophys Acta 1567: 23-33.
28. Faneca H, Simoes S, Pedroso de Lima MC (2004) Association of albumin or protamine to lipoplexes: enhancement of transfection and resistance to serum. J Gene Med 6: 681-692.
29. Koltover I, Salditt T, Radler JO, Safinya CR (1998) An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 281: 78-81.
30. Zuidam NJ, Barenholz Y (1998) Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery. Biochim Biophys Acta 1368: 115-128.
31. Harvie P, Wong FM, Bally MB (1998) Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J 75: 1040-1051.
32. Smith JG, Wedeking T, Vernachio JH, Way H, Niven RW(1998) Characterization and in vivo testing of a heterogeneous cationic lipid-DNA formulation. Pharm Res 15: 1356-1363.
33. Duarte S, Faneca H, Pedroso de Lima MC (2011) Non-covalent association of folate to lipoplexes: a promising strategy to improve gene delivery in the presence of serum. J Control Release 149: 264-272.
34. Faneca H, Faustino A, Pedroso de Lima MC (2008) Synergistic antitumoral effect of vinblastine and HSV-Tk/GCV gene therapy mediated by albumin-associated cationic liposomes. J Control Release 126: 175-184.
35. Pires P, Simoes S, Nir S, Gaspar R, Duzgunes N, Pedroso de Lima MC (1999) Interaction of cationic liposomes and their DNA complexes with monocytic leukemia cells. Biochim Biophys Acta 1418: 71-84.
36. Radler JO, Koltover I, Salditt T, Safinya CR (1997) Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science 275: 810-814.
37. Lasic DD (1996) Doxorubicin in sterically stabilized liposomes. Nature 380: 561-562.
38. Zelphati O, Nguyen C, Ferrari M, Felgner J, Tsai Y, Felgner PL (1998) Stable and monodisperse lipoplex formulations for gene delivery. Gene Ther 5: 1272-1282.
39. Lundberg D, Faneca H, Moran Mdel C, Pedroso de Lima MC, Miguel Mda G, Lindman B (2011) Inclusion of a single-tail amino acid-based amphiphile in a lipoplex formulation: effects on transfection efficiency and physicochemical properties. Mol Membr Biol 28: 42-53.
40. Li S, Tseng WC, Stolz DB, Wu SP, Watkins SC, Huang L (1999) Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection. Gene Ther 6: 585-594.
41. Sternberg B, Hong K, ZhengW, Papahadjopoulos D (1998) Ultrastructural characterization of cationic liposome-DNA complexes showing enhanced stability in serum and high transfection activity in vivo. Biochim Biophys Acta 1375: 23-35.
42. da Cruz MT, Cardoso AL, de Almeida LP, Simoes S, Pedroso de Lima MC (2005) Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. Gene Ther 12: 1242-1252.
43. Cardoso AL, Costa P, de Almeida LP, Simoes S, Plesnila N, Culmsee C, Wagner E, Pedroso de Lima MC (2010) Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo. J Control Release 142: 392-403.
44. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM (2004) Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 10: 3667-3677.
45. Lu Y, Low PS (2002) Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54: 675-693.
46. Reddy JA, Low PS (1998) Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 15: 587-627.
47. Saba NF, Wang X, Muller S, TighiouartM, Cho K, Nie S, Chen Z, ShinDM(2009) Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. Head Neck 31: 475-481.
48. Sudimack J, Lee RJ (2000) Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41: 147-162.
49. Meier R, Henning TD, Boddington S, Tavri S, Arora S, Piontek G, Rudelius M, Corot C, Daldrup-Link HE (2010) Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. Radiology 255: 527-535.
50. Campbell IG, Jones TA, Foulkes WD, Trowsdale J (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res 51: 5329-5338.
51. Laine C, Mornet E, Lemiegre L, Montier T, Cammas-Marion S, Neveu C, Carmoy N, Lehn P, Benvegnu T (2008) Folate-equipped pegylated archaeal lipid derivatives: synthesis and transfection properties. Chemistry 14: 8330-8340.
52. Li H, Piao L, Yu B, Yung BC, Zhang W, Wang PG, Lee JL, Lee RJ (2011) Delivery of calf thymus DNA to tumor by folate receptor targeted cationic liposomes. Biomaterials 32: 6614-6620.
53. Hofland HE, Masson C, Iginla S, Osetinsky I, Reddy JA, Leamon CP, Scherman D, Bessodes M, Wils P (2002) Folate-targeted gene transfer in vivo. Mol Ther 5: 739-744.
54. Rait AS, Pirollo KF, Xiang L, Ulick D, Chang EH (2002) Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 8: 475-486.
55. Chiu SJ, Marcucci G, Lee RJ (2006) Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes. Anticancer Res 26: 1049-1056.
56. Feng C, Wang T, Tang R, Wang J, Long H, Gao X, Tang S (2010) Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr Surg Int 26: 1185-1191.
57. Li P, Liu D, Sun X, Liu C, Liu Y, Zhang N (2011) A novel cationic liposome formulation for efficient gene delivery via a pulmonary route. Nanotechnology 22: 245104.
58. Medina-Kauwe LK, Xie J, Hamm-Alvarez S (2005) Intracellular trafficking of nonviral vectors. Gene Ther 12: 1734-1751.
59. Simoes S, Slepushkin V, Gaspar R, Pedroso de Lima MC, Duzgunes N (1998) Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides. Gene Ther 5: 955-964.
60. Simoes S, Slepushkin V, Pires P, Gaspar R, Pedroso de Lima MC, Duzgunes N (1999) Mechanisms of gene transfer mediated by lipoplexes associated with targeting ligands or pHsensitive peptides. Gene Ther 6: 1798-1807.
61. Yamauchi J, Hayashi Y, Kajimoto K, Akita H, Harashima H (2010) Comparison between a multifunctional envelope-type nano device and lipoplex for delivery to the liver. Biol Pharm Bull 33: 926-929.
62. Hatakeyama H, Ito E, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H (2009) A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J Control Release 139: 127-132.
63. Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U (2007) Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 21: 2664-2671.
64. Shenkman S, Araujo PS, Dijkman R, Quina FH, Chaimovich H (1981) Effects of temperature and lipid composition on the serum albumin-induced aggregation and fusion of small unilamellar vesicles. Biochim Biophys Acta 649: 633-641.
65. Garcia LAM, Shenkman S, Araujo PS, Chaimovich H (1983) Fusion of small unilamellar vesicles induced by bovine serum albumin fragments. Brazil J Med Res 16: 89-96.
66. Simões S, Slepushkin V, Pires P, Gaspar R, Pedroso de LimaMC, Düzgüne{ogonek}s N (2000) Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochimica et Biophysica Acta 1463: 459-469.
67. Aronsohn AI, Hughes JA (1998) Nuclear localization signal peptides enhance cationic liposome-mediated gene therapy. J Drug Target 5: 163-169.
68. Chan CK, Jans DA (1999) Enhancement of polylysine-mediated transfer infection by nuclear localization sequences: polylysine does not function as a nuclear localization sequence. Hum Gene Ther 10: 1695-1702.
69. Zanta MA, Belguise-Valladier P, Behr JP (1999) Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci USA 96: 91-96.
70. Branden LJ, Mohamed AJ, Smith CI (1999) A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol 17: 784-787.
71. Subramanian A, Ranganathan P, Diamond SL (1999) Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells. Nat Biotechnol 17: 873-877.
72. Chen J, Yu Z, Chen H, Gao J, Liang W (2011) Transfection efficiency and intracellular fate of polycation liposomes combined with protamine. Biomaterials 32: 1412-1418.
73. Hyndman L, Lemoine JL, Huang L, Porteous DJ, Boyd AC, Nan X (2004) HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release 99: 435-444.
74. Rudolph C, Plank C, Lausier J, Schillinger U, Muller RH, Rosenecker J (2003) Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 278: 11411-11418.
75. Trabulo S, Mano M, Faneca H, Cardoso AL, Duarte S, Henriques A, Paiva A, Gomes P, Simoes S, Pedroso de Lima MC (2008) S4(13)-PV cell penetrating peptide and cationic liposomes act synergistically to mediate intracellular delivery of plasmid DNA. J Gene Med 10: 1210-1222.
76. Trabulo S, Resina S, Simoes S, Lebleu B, Pedroso de Lima MC (2010) A non-covalent strategy combining cationic lipids and CPPs to enhance the delivery of splice correcting oligonucleotides. J Control Release 145: 149-158.
77. Miyata T, Yamamoto S, Sakamoto K, Morishita R, Kaneda Y (2001) Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1beta mediated by a tumor-specific vector, HVJ cationic liposomes. Cancer Gene Ther 8: 852-860.
78. Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O (2002) Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther 5: 609-616.
79. Faneca H, Cabrita AS, Simoes S, Pedroso de Lima MC (2007) Evaluation of the antitumoral effect mediated by IL-12 and HSV-tk genes when delivered by a novel lipid-based system. Biochim Biophys Acta 1768: 1093-1102.
80. Neves S, Faneca H, Bertin S, Konopka K, Duzgunes N, Pierrefite-Carle V, Simoes S, Pedroso de Lima MC (2009) Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell carcinoma in an immunocompetent murine model and mechanisms involved in the antitumoral response. Cancer Gene Ther 16: 91-101.
81. Li J, Li X, Zhang Y, Zhou XK, Yang HS, Chen XC, Wang YS, Wei YQ, Chen LJ, Hu HZ, Liu CY (2010) Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. J Gene Med 12: 481-490.
82. Troyer RM, Propst KL, Fairman J, Bosio CM, Dow SW (2009) Mucosal immunotherapy for protection from pneumonic infection with francisella tularensis. Vaccine 27: 4424-4433.
83. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 391: 806-811.
84. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
85. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, Polisky BA, Zinnen S (2005) Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41: 1349-1356.
86. Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK (2006) Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12: 4916-4924.
87. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C, Hadwiger P, Jayaraman M, John M, Jayaprakash KN, Maier M, Nechev L, Rajeev KG, Read T, Rohl I, Soutschek J, Tan P, Wong J, Wang G, Zimmermann T, de Fougerolles A, Vornlocher HP, Langer R, Anderson DG, Manoharan M, Koteliansky V, Horton JD, Fitzgerald K (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 11915-11920.
88. Yokota T, Iijima S, Kubodera T, Ishii K, Katakai Y, Ageyama N, Chen Y, Lee YJ, Unno T, Nishina K, Iwasaki Y, Maki N, Mizusawa H, Akari H (2007) Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C. Biochem Biophys Res Commun 361: 294-300.
89. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, Takimoto R, Takada K, Miyanishi K, Matsunaga T, Takayama T, Niitsu Y (2008) Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 26: 431-442.
90. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I (2006) RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
91. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I (2006) Post exposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193: 1650-1657.
92. Chien PY, Wang J, Carbonaro D, Lei S, Miller B, Sheikh S, Ali SM, Ahmad MU, Ahmad I (2005) Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 12: 321-328.
93. Li SD, Chono S, Huang L (2008) Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 16: 942-946.
94. Mendonca LS, Firmino F, Moreira JN, Pedroso de Lima MC, Simoes S (2010) Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or as ODN for chronic myeloid leukemia treatment. Bioconjug Chem 21: 157-168.
95. Mendonca LS, Moreira JN, Pedroso de Lima MC, Simoes S (2010) Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol Bioeng 107: 884-893.
96. Kumar P, Lee SK, Shankar P, Manjunath N (2006) A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med 3: e96.
97. Flynn MA, Casey DG, Todryk SM, Mahon BP (2004) Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm 1: 4.
98. Sorensen DR, Leirdal M, Sioud M (2003) Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327: 761-766.
99. Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C, Scherman D, Jorgensen C, Apparailly F (2006) Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54: 1867-1877.
100. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM, Lieberman J (2006) An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439: 89-94.
101. Zhang Y, Cristofaro P, Silbermann R, Pusch O, Boden D, Konkin T, Hovanesian V, Monfils PR, Resnick M, Moss SF, Ramratnam B (2006) Engineering mucosal RNA interference in vivo. Mol Ther 14: 336-342.
102. Jarver P, Langel U (2004) The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 9: 395-402.
103. Laufer SD, Restle T (2008) Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems. Curr Pharm Des 14: 3637-3655.
104. Gleave ME, Monia BP (2005) Antisense therapy for cancer. Nat Rev Cancer 5: 468-479.
105. Sazani P, Kole R (2003) Modulation of alternative splicing by antisense oligonucleotides. Prog Mol Subcell Biol 31: 217-239.
106. Tazi J, Bakkour N, Stamm S (2009) Alternative splicing and disease. Biochim Biophys Acta 1792: 14-26.
107. Kole R, Williams T, Cohen L (2004) RNA modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim Pol 51: 373-378.
108. Mercatante DR, Mohler JL, Kole R (2002) Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 277: 49374-49382.
109. Ko YT, Falcao C, Torchilin VP (2009) Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 6: 971-977.
110. Resina S, Abes S, Turner JJ, Prevot P, Travo A, Clair P, GaitMJ, Thierry AR, Lebleu B (2007) Lipoplex and peptide-based strategies for the delivery of steric-block oligonucleotides. Int J Pharm 344: 96-102.
111. Resina S, Kole R, Travo A, Lebleu B, Thierry AR (2007) Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides. J Gene Med 9: 498-510.
112. Thierry AR, Abes S, Resina S, Travo A, Richard JP, Prevot P, Lebleu B (2006) Comparison of basic peptides-and lipid-based strategies for the delivery of splice correcting oligonucleotides. Biochim Biophys Acta 1758: 364-374.
113. Thierry AR, Vives E, Richard JP, Prevot P, Martinand-Mari C, Robbins I, Lebleu B (2003) Cellular uptake and intracellular fate of antisense oligonucleotides. Curr Opin Mol Ther 5: 133-138.
114. Kim ST, Lee KM, Park HJ, Jin SE, Ahn WS, Kim CK (2009) Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J Gene Med 11: 26-37.
115. Zhang C, Newsome JT, Mewani R, Pei J, Gokhale PC, Kasid UN (2009) Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs. Methods Mol Biol 480: 65-83.
116. Beisner J, Dong M, Taetz S, Piotrowska K, Kleideiter E, Friedel G, Schaefer U, Lehr CM, Klotz U, Murdter TE (2009) Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 20-O-methyl-RNA. J Pharm Sci 98: 1765-1774.
117. Dinh TD, Higuchi Y, Kawakami S, Yamashita F, Hashida M (2011) Evaluation of osteoclastogenesis via NFkappaB decoy/mannosylated cationic liposome-mediated inhibition of pro-inflammatory cytokine production from primary cultured macrophages. Pharm Res 28: 742-751.
118. Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G, Nolta JA, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Madsen E, Snyder FF, Bastian J, Muul L, Blaese RM, Weinberg K, Parkman R (1998) T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34C cells in ADA-deficient SCID neonates. Nat Med 4: 775-780.
119. Baum BJ, Goldsmith CM, Kok MR, Lodde BM, van Mello NM, Voutetakis A, Wang J, Yamano S, Zheng C (2003) Advances in vector-mediated gene transfer. Immunol Lett 90: 145-149.
120. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, Furth EE, Propert KJ, Robinson MB, Magosin S, Simoes H, Speicher L, Hughes J, Tazelaar J, Wivel NA, Wilson JM, Batshaw ML (2002) A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 13: 163-175.
121. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
122. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
123. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
124. Edelstein ML, Abedi MR, Wixon J (2007) Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 9: 833-842.
125. Alton EW, SternM, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM (1999) Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebocontrolled trial. Lancet 353: 947-954.
126. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, Gooi HC, Goddard CA, Hannavy K, Smyth SE, Egan JJ, Sorgi FL, Huang L, Cuthbert AW, Evans MJ, Colledge WH, Higgins CF, Webb AK, Gill DR (2000) Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 7: 1156-1165.
127. Yoshida J, Mizuno M, Fujii M, Kajita Y, Nakahara N, Hatano M, Saito R, Nobayashi M, Wakabayashi T (2004) Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther 15: 77-86.
128. Bedikian AY, Richards J, Kharkevitch D, AtkinsMB, Whitman E, Gonzalez R (2010) A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 20: 218-226.
129. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC (2001) Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19: 3422-3433.
130. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, Kracht L, Coenen HH, Sturm V, Wienhard K, Heiss WD, Jacobs AH (2003) Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54: 479-487.
131. Cavazzana-Calvo M, Thrasher A, Mavilio F (2004) The future of gene therapy. Nature 427: 779-781.
132. Hyde SC, Gill DR, Higgins CF, Trezise AE, MacVinish LJ, Cuthbert AW, Ratcliff R, Evans MJ, Colledge WH (1993) Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362: 250-255.
133. McLachlan G, Ho LP, Davidson-Smith H, Samways J, Davidson H, Stevenson BJ, Carothers AD, Alton EW, Middleton PG, Smith SN, Kallmeyer G, Michaelis U, Seeber S, Naujoks K, Greening AP, Innes JA, Dorin JR, Porteous DJ (1996) Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP. Gene Ther 3: 1113-1123.
134. Griesenbach U, Ferrari S, Geddes DM, Alton EW (2002) Gene therapy progress and prospects: cystic fibrosis. Gene Ther 9: 1344-1350.
135. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, Nunez-Alonso G, Green AM, Bazzani RP, Sumner-Jones SG, Chan M, Li H, Yew NS, Cheng SH, Boyd AC, Davies JC, Griesenbach U, Porteous DJ, Sheppard DN, Munkonge FM, Alton EW, Gill DR (2008) CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 26: 549-551.
136. Griesenbach U, Alton EW (2009) Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 61: 128-139.
137. Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, Yoshida J (2008) A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med 10: 329-339.
138. Hung MC, Chang JY, Xing X (1998) Pre-clinical and clinical study of HER-2/neu-targeting cancer gene therapy. Adv Drug Deliv Rev 30: 219-227.
139. Villaret D, Glisson B, Kenady D, Hanna E, Carey M, Gleich L, Yoo GH, Futran N, Hung MC, Anklesaria P, Heald AE (2002) A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 24: 661-669.